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Introduction
Urothelial carcinoma (UC) of the bladder is the sixth most common cancer in the USA and UK (>70,000 and >10,000 new cases per annum respectively). The majority of tumors (70%) are low-grade (grade 1/2), low-stage (Ta) lesions not penetrating the basement membrane and these infrequently progress to muscle invasion (10-15%). However, tumor recurrence is a major feature and the need for repeated cystoscopic monitoring places a great burden on both Frequent genomic alterations include copy number loss and/or loss of heterozygosity (LOH) involving chromosome 9 in UC of all stages and grades, FGFR3 and PIK3CA mutation in low-grade Ta tumors (2) and TP53 mutation and inactivation of the retinoblastoma (RB) pathway in MI tumors (3, 4) . High-throughput methodologies at the mRNA, miRNA, protein, epigenetic, and copy number levels have reported associations with clinico-pathological characteristics. These include mRNA and microRNA expression signatures associated with distinct clinico-pathological features (5, 6 ) and a range of aberrant methylation or histone modifications e.g. (7, 8) . Although some expression signatures have been validated in independent sample series (9) , the use of such markers in the clinic remains unproven. Genomic sub-groups of urothelial carcinoma 5 DNA copy number differences underlie a significant proportion of differences in gene expression detected between cancer subtypes and studies in other tumor types have described prognostic subtypes based on DNA copy number alterations. In addition, DNA represents a more stable template for marker assessment than RNA. The use of DNA copy number profiles to define molecular subtypes of UC, and the relationships between copy number, mutational events and clinico-pathological data have not been fully assessed. Genome-wide analysis of copy number aberrations and LOH using array-based CGH or SNP array profiling have revealed regions of alteration (10) (11) (12) (13) (14) (15) . In general, fewer copy number alterations are found in low-stage and -grade tumors, and more complex patterns in MI tumors. Several regions of high-level amplification have been identified (14, 16) and integration of copy number and expression data has identified candidate genes (14) . A few studies have searched for concomitant copy number events (14, 17) , or have combined assessment of copy number alterations with mutation status of FGFR3 or TP53 and found differences in chromosomal stability relating to mutation (11, 18) . Copy number alterations have been associated with stage, grade, recurrence, carcinoma in situ (CIS) and outcome (12, 13, 19, 20) , but few studies have performed in-depth correlations of findings with clinico-pathological information, and where this has been done, mutation status was not assessed (21) , full copy number information was not included in the analysis (22) , or tumors of all stages and grades together were subdivided on the basis of gene expression profiles prior to copy number analysis (23) .
We predict that further genomic subdivision of UC remains to be revealed, and that this may be achieved through integrated analysis of genomic events in large panels of tumors.
Here, we assessed 160 bladder tumors, including the largest panel of T1G3 tumors analyzed to date (n=49), for both genome-wide copy number alterations and mutation of 8 key genes implicated in UC. We identified concomitant molecular events and assessed the relationships of molecular alterations to clinicopathological data. Potential subclasses of the "gold-standard"
Research. Genomic sub-groups of urothelial carcinoma 6 grade/stage groups of UC defined by DNA copy number and mutation status have been identified.
Materials and Methods

Patient samples and clinical information
Study approval was granted by the Leeds-East Research Ethics Committee and informed consent obtained from all patients. Cold cup biopsies were snap-frozen and stored in liquid nitrogen and the remainder of the sample embedded in paraffin for diagnostic assessment (24, 25). The sample set consisted of 3 TaG1, 39 TaG2, 16 TaG3, 11 T1G2, 49 T1G3, and 42 ≥T2 (all grades) tumors (Supplementary Table 1 ). Median follow-up time was 6 years.
Nucleic acid isolation
DNA was extracted from frozen sections containing at least 70% tumor cells using the QIAamp DNA Mini Kit (Qiagen). DNA was extracted from venous blood using a Nucleon DNA extraction kit (Nucleon Biosciences) or by salt precipitation. Total RNA was extracted using the PicoPure RNA Isolation Kit (Nikon UK Limited).
Array Comparative Genomic Hybridisation (array-CGH)
Two types of 1-Mb resolution comparative genomic hybridisation (CGH) array were used; Centre for Microarray Resources (University of Cambridge, Cambridge, UK) and Sanger (26) . Coverage on the two arrays was essentially the same (details available on request). Hybridisation was as described (16) . Reference samples were paired normal DNA from blood. In 54 cases blood DNA was not available at the time of CGH analysis and an unmatched lymphoblastoid cell line was used. BlueFuse software (BlueGnome) was used to Genomic sub-groups of urothelial carcinoma 7 define spots, subtract background and calculate normalised fluorescence intensities.
Breakpoints and regions of gain and loss were detected using the BlueFuse software aCGHsmooth algorithm (27) with calling thresholds for determining copy number gain and loss set to +/-0.15 log 2 ratio (test/reference) for Centre for Microarray Resources (CMR) arrays or +/-0.2 for Sanger arrays. These thresholds were determined by observation of normal samples and samples with known changes. Alterations were confirmed visually by 2 observers.
Amplifications and homozygous deletions (HD) were defined where the log 2 ratio was ≥1. 
Mutation Analysis
High-resolution melting (HRM) curve analysis was used to screen for mutations in FGFR3, PIK3CA, HRAS, KRAS, and NRAS (28) . Fluorescent single-stranded conformational polymorphism (F-SSCP) analysis or HRM analysis was used to screen TSC1 (28) and TP53. AKT1 mutations were detected as described (29) . GRIN2A was analyzed using HRM analysis or direct sequencing. Potential mutations were confirmed by sequencing tumor and matched blood samples to establish somatic mutation status. Primer sequences and protocols are available for TP53 and GRIN2A on request.
Loss of heterozygosity analysis
Microsatellite markers in the CDKN2A region (D9S1748, D9S1749), TSC1 region Genomic sub-groups of urothelial carcinoma 8 3130 sequencer (Applied Biosystems) and analyzed using GeneMapper v3.7 software (Applied Biosystems). LOH was scored as a reduction of at least 60% signal from one allele.
Immunohistochemistry
Sections were stained for FGFR3 (1:200; B9; Santa Cruz), PTEN (1:100; 9559; Cell Signaling Technology), p53 (1:100; 18-01; Novacastra) and USP7 (1:100; IHC-00018; Bethyl Laboratories Inc.). All runs included a no primary antibody control.
Statistics and cluster analysis
Smoothed log 2 ratio values were used for frequency plot visualisation and statistical comparisons of frequency data within the Nexus Copy Number Professional 3.1 Software (Hs04233493_sH), GRHL2 (Hs00227745_m1) and GRIN2A (Hs00168219_m1). Levels of expression were normalised to SDHA (Hs00417200_m1) and measured relative to a pool of uncultured normal human urothelial cells isolated from human ureters obtained at nephrectomy (30) .
Results
Relationship of genome-wide copy number alterations to tumor stage and grade
1Mb-resolution array-CGH was used to assess copy number alterations in 160 UC samples. Tumor grade and stage currently form a major component in assessment of risk of progression in non-muscle-invasive bladder cancer (31) . Thus, we first constructed frequency plots of DNA copy number alterations according to stage and grade ( Figure 1 ). We next examined whether the proportions of different types of alteration (i.e. those involving whole chromosomes, chromosome arms or smaller regions) differed between stages and grades. No significant differences were observed but the frequencies of such alterations increased with stage and grade ( Table 1) .
Molecular alterations involving chromosome 9
Deletion of all or part of chromosome 9 is common in UC and critical regions have been identified at 9p21.3 (CDKN2A, CDKN2B), 9q22 (PTCH), 9q33 (DBC1) and 9q34
Research. 
Other regions of homozygous deletion and high-level amplification
Fifty-one HD, including those on chromosome 9 were detected in 29 tumors (Table 2) . Table   2 ). The most frequent (n=11) was on 11q13.2-q13.3 (containing CCND1). Other regions were 3p25.3-p25.1, 8q22.2-q22.3 and 12q15 (containing RAF1, YWHAZ and MDM2 respectively).
Research. Table 1 ). FGFR3 mutation (n=77) was associated with low stage (p < 0.0001) and grade (p < 0.0001) and TP53 mutation (n=44) with high stage (p < 0.0001) and grade (p < 0.0001). Eleven tumors had both FGFR3 and TP53 mutation. Forty-one PIK3CA, 22 TSC1, 7 HRAS, 7 KRAS, 1 NRAS and 5 AKT1 mutations were detected and had no association with stage or grade.
Fraction of genome altered
Fraction of genome altered (FGA) was defined as the percentage of clones reporting significantly altered copy number and provides a measure of chromosomal instability. FGA groups A (<1%), B (1-<10%), C (10-<30%) and D (≥30%) were defined (Supplementary Table 1 ). Median FGA was higher in tumors of higher grade and stage (Supplementary Figure   1) . Some tumors exhibited few or no copy number alterations. Thirty-five had <5% FGA and 19 of these had <1% FGA. The majority of these chromosomally stable tumors were of low stage and grade (TaG1 n=3; TaG2 n=21; TaG3 n=4; T1G2 n=2; T1G3 n=3; T3G3 n=2).
Research. wild-type Ta tumors commonly showed gain of the long arm of chromosome 8 (p<0.0001).
This inverse relationship was also found in FGFR3 mutant (n=22) and wild-type (n=27) T1G3 tumors (p<0.0001) ( Figure 3B ). In most cases, all of 8q was gained but four tumors showed focal amplification (Supplementary Figure 2A) . The minimal region (8q22.2-q22.3) contained 13 genes (ANKRD46-KLF10). A previous study at tiling path resolution identified a core region extending over 1.8Mb from POLR2K to NCALD and revealed strongest correlation between YWHAZ copy number and expression (14) . Information from this and the present study defines a minimal region (ANKRD46-NCALD) (Supplementary Figure 2B) . We measured expression of YWHAZ, and five other genes (ANKRD46, SNX31, ZNF706, NACAP1 and GRHL2) in 46 T1G3 tumors, including those with amplification. YWHAZ showed the best correlation (r=0.61554; p=0.000005) (Supplementary Figure 2C) .
PIK3CA and FGFR3 mutation are commonly found together in UC (2) . Compatible with this, we found that as for FGFR3 mutation, PIK3CA mutation was associated with a lower FGA in Ta (p=0.003), T1 (p=0.02), G2 (p=0.01) and G3 (p=0.005) tumors. No relationships between TSC1 or RAS gene mutation, FGA and/or copy number events were observed.
Higher FGA was associated with TP53 mutation in T1, T2 and grade 3 tumors 
Genomic sub-groups of urothelial carcinoma 13 mutant tumors had low FGA. A comparison of specific copy number alterations in TP53 mutant (n=24) and wild-type (n=18) ≥T2 samples revealed significant differences ( Figure 2B ).
Deletions on 2q, 4q, 11p, 10q, 13q, 14q, 16p, 16q and 19p and gains on 1p, 8q, 10q and 12q were positively associated with TP53 mutation. A region extending from 16p13.2 to 16p13.3 (6,846,409-10,432,694bp) had the best p-value, and contains 10 genes (A2BP1-ATF7IP2).
The same association of 16p loss with TP53 mutation was not detected in T1G3 tumors.
Two genes from 16p13.2-p13.3 (USP7 and GRIN2A) were studied further. The deubiquitinating enzyme USP7 (HAUSP) was considered a good p53-related candidate, and 
PTEN deletion (p = 0.00003; log-rank test). As TP53 mutation and loss of RB1 are frequent events in muscle invasive UC, we performed similar analyses. TP53 mutation had no effect either alone or in combination with PTEN copy number loss. RB1 copy number loss had a non-significant (p = 0.053; log-rank test) trend for association with shorter time to metastasis when assessed alone, and significant association (p = 0.0002; log-rank test) in combination with PTEN loss (Supplementary Figure 3) . We also examined PTEN protein expression by IHC (Supplementary Figure 4) . However it was PTEN copy number that showed the strongest association with metastasis. Supplementary Figure 4 summarises the relationships between clinical outcome data and alterations involving selected components of the RB/p53/PI3-kinase-related pathways and common regions of amplification.
Tumor subgroups based on genomic profile
A key aim was to search for novel genomic sub-groups to provide improved subclassification at diagnosis. One-way unsupervised hierarchical cluster analysis on copy number data separated tumors primarily but not exclusively according to stage and grade into 3 main clusters (Supplementary Figure 5A) . We then used the same approach to assess heterogeneity within tumor subgroups (Ta, T2, T1G3) in relation to FGA and mutation data. Cluster 3 contained mainly grade 3 tumors (n=8) with high levels of chromosomal instability.
Gain of 8q was a feature of this cluster and was mutually exclusive with FGFR3 mutation.
The remaining TaG3 tumors were spread across all other clusters. No association was found between local disease recurrence or multifocality and cluster assignment. Table 3 ; Supplementary Figure 6 ). Of the 3 primary T1G3 clusters, Cluster 2 showed the highest clone loss:gain ratio (3.9:1) and this prevalence of losses was also evident when separate events were assessed. Ta Cluster 2a also showed a high clone loss:gain ratio (2.7:1). Several other clusters showed an excess of losses, in most cases due to loss of all or most of chromosome 9.
In samples that metastasized, we examined copy number alterations and mutation in detail. All 4 tumors from T1G3 Cluster 2 had loss of distal 2q, chromosome 9 and 13q including RB1. Three also had loss of 10q and the other had TSC1 mutation. In addition, three were TP53 mutant and one had MDM2 amplification. The Cluster 1 sample that metastasized had a homozygous deletion of PTEN, MDM2 amplification and loss of RB1.
Discussion
The clinical and pathological heterogeneity of bladder cancer presents a challenge in disease management. It is likely that combined molecular and histopathological classification will provide optimal tools for informed clinical decision-making. Here we have identified novel regions of copy number alteration, elucidated relationships between molecular alterations and clinicopathological features, uncovered relationships between molecular events and revealed novel genomic subgroups.
Previous studies have identified two groups of UC based on chromosomal alterations (3, 4) . Here, we confirmed the distinction between low-grade Ta tumors, with low complexity of chromosomal changes, frequent FGFR3 mutation and infrequent TP53 mutation, and muscle-invasive (MI) tumors, with more complex chromosomal changes, infrequent FGFR3 mutation and frequent TP53 mutation. Hierarchical cluster analysis of copy number events in the entire series generated 3 main clusters primarily according to stage and grade. We then assessed the complexity of chromosomal changes within these diagnostic histopathological groups to identify additional features that improve biological understanding or have clinical utility.
One cluster of Ta tumors had strikingly few copy number alterations (<1% FGA).
These were characterized by point mutations, including 74% in FGFR3. Almost certainly, further heritable events remain to be identified in this group. Some Ta tumors showed considerable complexity of chromosomal changes. Sub-cluster (2a) was characterized by no chromosome 9 loss, a common event in other clusters, and these showed more widespread changes than Cluster 2b and represent an interesting group for further analysis. Cluster 3 contained the majority of grade 3 tumors, with high FGA and similar alterations to T2 tumors.
T2 tumors also comprised 3 clusters, all with high chromosomal complexity. It was reported that MI tumors with higher FGA had poorer prognosis (12) , but this was not clear here.
Although we identified no association between cluster assignment and disease recurrence in Ta or metastasis and survival in T2 groups, numbers in the final clusters are relatively small. Analysis of much larger numbers is needed to assess this and to define sub-group signatures.
T1G3 tumors represent an intermediate and heterogeneous group. This is a clinically challenging group, in which the decision to give conservative local treatment with close surveillance, or radical cystectomy, is currently made in the absence of validated prognostic biomarkers. The 49 tumors analyzed here represent the largest series analysed for mutation and copy number alterations. Previously a large series of T1G3 tumors was assessed for FGFR3 and TP53 mutation. Unlike Ta tumors in which these mutations are virtually mutually exclusive, mutations were independently distributed (34) . We confirmed this independent distribution, though here the overall frequency of FGFR3 mutation was higher and TP53 frequency lower. This indicates the existence of distinct T1G3 subgroups.
In support of this, we defined 3 major T1G3 clusters and a 4 th smaller cluster that differed with respect to both copy number events and FGFR3 and TP53 mutation status.
Cluster 1 had frequent FGFR3 mutation (69.2%), with few alterations apart from losses of 17p and chromosome 9, and gains of 1q, 7 and 15. Cluster 3 were FGFR3 wild-type and mostly TP53 mutant (71%), with more complex chromosomal changes but strikingly low frequency of chromosome 9 loss. Cluster 4 comprised three highly chromosomally unstable samples. Cluster 2 tumors contained fewer alterations than Cluster 3 but showed the highest rate of stage progression/metastasis. Interestingly, these had a prevalence of copy number losses rather than gains. A recent conventional CGH study of 67 Ta and T1 UC, including 21 T1G3 tumors, defined 3 groups with even distribution of the T1G3 cases, and found that those with more losses had worst outcome (15) . Similarly, an analysis of lung cancer showed that copy number loss was associated with reduced survival (35) . Such profiles may reflect inactivation of multiple tumor suppressor genes. Due to small numbers of patients with
adverse outcome, we cannot define a progression classifier, but some combinations of genomic events were apparent in samples that progressed, including p53 pathway alterations (TP53 mutation or MDM2 amplification), RB1 loss and losses of 2q, 9q and 10q (PTEN).
The distinct characteristics of these T1G3 subgroups and the independent distribution of events shared by low-grade Ta or MI UC may indicate either different developmental pathways for one or more of these T1G3 groups, or an origin in one or other of the two major pathogenesis pathways e.g. as CIS or a low-grade Ta Several putative mRNA targets of Hu proteins have been identified including the cyclin dependent kinase inhibitor p21 (38) . HD of ELAVL2 has been reported in other cancers (39, 40) and mutation in glioblastoma (40) . We also detected HD at 9p24.2-p24.3 and 9p22.2-p22.3. HD at 9p24 and 9p23 were detected previously in UC (14) . We also found HD of DAPK1, hypermethylation of which has been reported in UC previously (41) . Nextgeneration sequencing should clarify the status of all chromosome 9 genes. Indeed, exome sequencing of 9 invasive UC, detected mutations in several genes on chromosome 9 including DOCK8, which showed HD here (42).
We detected amplification at 9p24.3 and 9p23-p24.3 and regions of gain at 9p13.3-p21 and 9q21.12. Amplifications at 9p13.3 and 9p22.3-p24.3 are reported in carcinomas of tongue and larynx (43) and in glioma, with GLIS3 implicated as a 9p23candidate gene (44) .
Amplification of 9p21.3-pter in seminomas is associated with overexpression of DNMT1 (45).
Our observations suggest that copy number increases on chromosome 9 should be further elucidated in UC.
The observed FGFR3 mutation distribution is compatible with previous studies suggesting that this is a key event in non-invasive tumors with good prognosis (46) that are chromosomally stable (18) . An inverse relationship between FGFR3 mutation status and gains of chromosome 6, 8q and 11q in Ta tumors was reported (18) and gains of 8q11.23-q24.21 in FGFR3 wild-type tumors (47) . Here, FGFR3 mutation and overrepresentation of 8q were mutually exclusive in all non-muscle-invasive tumors and in T1G3 tumors. Several tumors had high-level amplification at 8q22.2-q22.3, which has been associated with more aggressive UC phenotype [e.g. (12, 14, 17) ]. Based on current and published data (14) YWHAZ (14-3-3-zeta) is a good candidate gene and potential therapeutic target. Compatible with this, amplification and overexpression contributes to chemotherapy resistance and recurrence of breast cancer (48) . The 14-3-3 protein family regulate many pathways in normal and cancer cells by interacting with key target proteins. Indeed, the binding and sequestering of pro-apoptotic proteins by YWHAZ has been implicated in the development of castrationresistant prostate cancer (49) .
We found a subgroup of T2 tumors with TP53 mutation and concomitant 16p13.2-p13.3 deletion. 16p LOH and deletion in UC is associated with high-grade and progression (10) . Although USP7 and GRIN2A appeared good 16p candidates, we found no evidence for their inactivation. However, as several deletions involved larger regions or the whole of 16p, more than one candidate region cannot be discounted. For example, TSC2 is outside the minimal region and mutations were recently detected in UC (50). However, it should be noted that here, copy number losses of 16p that included TSC2 were not mutually exclusive with alterations involving TSC1.
In MI tumors, we found association between metastasis and 10q loss, including PTEN.
Previous studies have reported loss of PTEN in invasive UC (28) and conditional knockout mouse models show that Pten loss with p53 or Lkb1 loss leads to invasive and metastatic UC (51, 52). We found no association between LKB1 deletion and metastasis and when both PTEN deletion and TP53 mutation were examined, PTEN copy number loss alone best predicted metastasis. 
